CDX2 and colorectal cancer: However, as only two out of 1039 CRCs (0.2%) showed a complete loss of both SATB2 and CDX2, and the majority of SATB2 negative CRCs showed a strong and diffuse expression of CDX2 (and vice versa), a combined panel of both markers appears to be able to identify the overwhelming majority of colorectal cancers and is probably the most expedient approach for routine diagnostic settings.